BioNTech SE (BNTX)

BioNTech SE Income Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	3,819	17,311	18,977	482.3	108.6
Revenue Growth (YoY)	-77.94%	-8.78%	3834.63%	344.11%	-14.87%
Cost of Revenue	599.8	2,995	2,912	59.3	17.4
Gross Profit	3,219	14,316	16,065	423	91.2
Selling, General & Admin	557.7	541.2	327.2	108.5	48.2
Research & Development	1,783	1,537	949.2	645	226.5
Other Operating Expenses	188	-405.3	-495	-248.1	-2
Operating Expenses	2,529	1,673	781.4	505.4	272.7
Operating Income	690.4	12,643	15,284	-82.4	-181.5
Interest Expense / Income	23.9	18.9	305.1	65	2
Other Expense / Income	-519.6	-330.3	-67.7	-1.6	-4.2
Pretax Income	1,186	12,954	15,046	-145.8	-179.3
Income Tax	255.8	3,520	4,754	-161	-0.2
Net Income	930.3	9,434	10,293	15.2	-179.1
Net Income Growth	-90.14%	-8.34%	67613.82%	-	-
Shares Outstanding (Basic)	238	243	244	227	226
Shares Change	-2.18%	-0.55%	7.76%	0.23%	-
EPS (Basic)	3.87	38.78	42.18	0.06	-0.85
EPS (Diluted)	3.83	37.77	39.63	0.06	-0.85
EPS Growth	-89.86%	-4.69%	65950.00%	-	-
Free Cash Flow	4,666	13,215	739.1	-97.7	-269.6
Free Cash Flow Per Share	19.63	54.38	3.02	-0.43	-1.19
Dividend Per Share	-	2.111	-	-	-
Gross Margin	84.29%	82.70%	84.66%	87.70%	83.98%
Operating Margin	18.08%	73.03%	80.54%	-17.08%	-167.13%
Profit Margin	24.36%	54.50%	54.24%	3.15%	-164.92%
Free Cash Flow Margin	122.18%	76.34%	3.89%	-20.26%	-248.25%
Effective Tax Rate	21.57%	27.17%	31.59%	-	-
EBITDA	1,393	13,096	15,427	-42.1	-143.4
EBITDA Margin	36.49%	75.65%	81.29%	-8.73%	-132.04%
Depreciation & Amortization	183.4	123.3	75.2	38.7	33.9
EBIT	1,210	12,973	15,352	-80.8	-177.3
EBIT Margin	31.68%	74.94%	80.90%	-16.75%	-163.26%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).